Newscast – Page 178 – media

Plexus TG and Codonics to integrate anaesthesia safety technology

Medication management systems provider Plexus Technology Group (TG) is set to integrate its anaesthesia information management system (AIMS) with medical imaging firm Codonics’ medication safety technology Safe Label System (SLS) for an improved anaesthesia process.
- Source: Medicaldevices-network.com
- 368
- August 1, 2017
anaesthesia Company Insight
AZ, Merck link to develop and commercialise cancer drugs

AstraZeneca and Merck & Co have announced a global strategic oncology collaboration to co-develop and co-commercialise the former’s Lynparza and selumetinib for multiple cancer types.
- Source: pharmatimes
- 493
- July 31, 2017
cancer Lynparza Market Views Researches therapy
EU approves CV benefit claim for Novo’s Victoza

Novo Nordisk’s diabetes drug Victoza is now approved in Europe as the only GLP-1 analogue with a label including prevention of cardiovascular events.
- Source: pharmatimes
- 435
- July 31, 2017
cardiovascular Company Insight diabetes New Approvals
Medtronic launches new MRI cardiac therapy defibrillators

Medtronic’s Canadian subsidiary has launched its new magnetic resonance imaging (MRI) conditional cardiac resynchronisation therapy defibrillators (CRT-Ds)
- Source: Medicaldevices-network.com
- 512
- July 31, 2017
cardiac Company Insight heart MRI
EU OKs first-line use of AZ’ Faslodex

EU regulators are permitting the use of AstraZeneca’s breast cancer drug Faslodex at an earlier stage of the treatment pathway in patients with certain forms of the disease.
- Source: pharmatimes
- 764
- July 28, 2017
breast cancer EU inhibitor New Approvals
Takeda and BioSurfaces to develop new medical devices for GI indications

Japan's Takeda Pharmaceutical Company has signed an agreement with US-based nanotechnology provider BioSurfaces to develop new therapeutic devices to treat gastrointestinal (GI) diseases.
- Source: Medicaldevice-network
- 423
- July 28, 2017
Company Insight gastrointestinal nanofibrous New Approvals
Sensus gets Chinese regulatory approval for keloid device

US-based Sensus Healthcare has received approval from the China Food and Drug Administration (CFDA) to commercialise its keloid prevention and treatment device, SRT-100. The tool is designed to deliver a precise and calibrated dose of superficial radiation therapy to ensure a skin deep and safe treatment for patients. The low-dose radiation is intended to destroy keloid-causing non-malignant tumour cells, basal cell carcinoma and squamous cell carcinoma without the use of anaesthesia, risk of infection, scarring or the need for reconstructive plastic surgery. Sensus intends to introduce SRT-100 into the country’s market in the fourth quarter of this year through its Chinese partner Chindex Medical, which is a division of Fosun Pharma International. The device will focus on prevention and treatment of keloids associated with Cesarean sections (C-sections). Sensus Healthcare CEO Joe Sardano said: “CFDA clearance of the SRT-100 for the treatment and prevention of keloids is an important milestone for ...
- Source: Medicaldevice-network
- 450
- July 28, 2017
CFDA Company Insight keloid New Approvals
ViiV’s long-acting two-drug HIV regimen hits targets

A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence. The LATTE-2 study assessed long-acting, injectable formulations of cabotegravir (ViiV) and rilpivirine (Janssen, branded Edurant), given every four or eight weeks to patients with HIV-1 infection who had already achieved viral suppression with a daily three-drug oral regimen of cabotegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs). Following 96 weeks of maintenance treatment, viral suppression rates for the two-drug regimen dosed every eight weeks (94 percent) or every four weeks (87 percent) were comparable to the rate observed in patients continuing with a three-drug oral regimen (84 percent). In the study, data from which were published in The Lancet and presented at the annual conference ...
- Source: Medicaldevice-network
- 511
- July 27, 2017
Clinical Trials formulation HIV Researches
FDA clears BD’s immunological IVD system for commercialization

FDA has granted 510(k) clearance to Becton, Dickinson and Company’s (BD) in-vitro diagnostic (IVD) device, FACSLyric flow cytometer system.
- Source: Medicaldevice-network.com
- 525
- July 27, 2017
Clinical FDA immune New Approvals
SLU begins trial for device to treat postpartum haemorrhage

US-based Saint Louis University (SLU) Care has started a clinical trial to evaluate the InPress Postpartum Haemorrhage Intrauterine device as a potential treatment to stop excessive bleeding for mothers after childbirth.
- Source: Medicaldevice-network.com
- 511
- July 27, 2017
Clinical Trials hemorrhage

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.